Last reviewed · How we verify

NCT02125981

The Study About the Efficacy of Oral Limaprost After Surgery for Cervical Myelopathy

Completed Phase 3 Last updated 14 April 2023
What this trial tests

Phase 3 trial testing Limaprost in Cervical Myelopathy in 160 participants. Completed in 1 April 2023.

Timeline
1 September 2014
Primary endpoint
1 October 2022
1 April 2023

Quick facts

Lead sponsorSeoul National University Hospital
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment160
Start date1 September 2014
Primary completion1 October 2022
Estimated completion1 April 2023
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Seoul National University Hospital

Who can join

20 and older, any sex, with Cervical Myelopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The limaprost alfadex can improve the surgical outcomes in patients with cervical myelopathy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Pharmacological Treatment of Degenerative Cervical Myelopathy: A Critical Review of Current Evidence.
    Levett JJ, Georgiopoulos M, Martel S, Mugheiry WA, et al · · 2024 · cited 7× · PMID 38955515 · DOI 10.14245/ns.2448140.070

Verify or expand the search:

Other recruiting trials for Cervical Myelopathy

Currently open trials in the same condition.

Other Seoul National University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02125981.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing